179530 · KOSDAQ · ₩179530 · 애드바이오텍
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−50.4% from the high
₩1,300Today: ₩1,902 – ₩2,050₩3,995
Returns
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals describe activity, not recommendations. Not financial advice.
Adbiotech (애드바이오텍, KRX: 179530) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is an eco-friendly biotech firm in South Korea that develops immune antibodies and specific antibodies as alternatives to vaccines and antibiotics for livestock, aquaculture, and human use. Its shares closed at ₩1,983 on Oct 27, 2026, up 3.17% on the day, giving it a market value of ₩62B.
The company is an eco-friendly biotech firm in South Korea that develops immune antibodies and specific antibodies as alternatives to vaccines and antibiotics for livestock, aquaculture, and human use. Its core platforms are IgY egg-yolk antibodies, VHH (nanobody) antibodies, scFv antibodies including for avian influenza, and the BA01 microbial product. Its main products include veterinary medicines, feed supplements, shrimp feed additives, a food-waste treatment microbial product, and pet eye-care products, with sales to livestock farms and exports to Southeast Asia.
Written by AI from the company's latest annual report.
Predicted impact: Low· Actual: −17.2% vs sector, volume 0.2× normal (5 trading days)
Distribution tie-up in Central Asia; no size or revenue impact disclosed, so small.
Predicted impact: Low· Actual: −17.2% vs sector, volume 0.2× normal (5 trading days)
Small regional distribution partnership in Kazakhstan; no financial size given and immaterial to revenue.
Titles in Korean until English translations are added.
Also known as: Adbiotech / 애드바이오텍 / 179530 / KRX:179530
Source: KRX statistical information